← FDA DRUG APPROVALS

FDA ANDA · ANDA084326

NITROFURANTOIN

Sponsor: WATSON LABS

APPLICATION
ANDA084326
TYPE
ANDA
LATEST ACTION
1986-02-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

NITROFURANTOINDiscontinued
NITROFURANTOIN 50MG · CAPSULE · ORAL
NITROFURANTOINDiscontinued
NITROFURANTOIN 100MG · CAPSULE · ORAL

Approval history

1986-02-06Manufacturing (CMC) · Supplement 72AP
1986-02-06Manufacturing (CMC) · Supplement 73AP
1986-02-06Manufacturing (CMC) · Supplement 71AP
1984-07-06Manufacturing (CMC) · Supplement 64AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →